Merus (MRUS) said Tuesday that petosemtamab in combination with pembrolizumab has received breakthrough therapy designation from the US Food and Drug Administration.
The combination therapy has been designated as the first-line treatment for adult patients with recurrent or metastatic programmed death-ligand 1 positive head and neck squamous cell carcinoma, according to updated data from an ongoing phase 1/2 trial, the company said.
Merus said that with the designation, it plans to hold discussions with the FDA about the company's goal of submitting a potential biologics license application.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.